Personal profile
Expertise
- Basic and translational research in multiple myeloma
- Research for therapies, targeting the myeloma cell in its microenvironment
- Study of functional interaction between the cancer cell and its microenvironment using microarray, realtime PCR and FACS analysis and westernblotting.
- Investigate the influence of histon deacetylase inhibitors (HDAC-I) in 5TMM models.
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
ANI432: Interferon Signaling as a Regulator of Cancer Cell Dormancy and Immune Suppression in Multiple Myeloma
Vanderkerken, K. (Administrative Promotor) & De Veirman, K. (PI (Promotor, Principal Investigator))
1/10/25 → 30/09/29
Project: Fundamental
-
EUAR240: JANE2: Joint Action on Networks of Expertise on Cancer
Neyns, B. (CoI (Co-Promotor)), Rooman, I. (CoI (Co-Promotor)), Beernaert, K. (CoI (Co-Promotor)), Giron, P. (CoI (Co-Promotor)), De Ridder, M. (CoI (Co-Promotor)), De Becker, A. (CoI (Co-Promotor)), Van Riet, I. (CoI (Co-Promotor)), Hes, F. J. (CoI (Co-Promotor)), Rogiers, A. (CoI (Co-Promotor)), Houbracken, I. (CoI (Co-Promotor)) & Vanderkerken, K. (Administrative Promotor)
1/11/24 → 31/10/28
Project: Applied
-
BASGO38: OZR Basisfinanciering voor Grote Onderzoeksgroepen - TORC
Vanderkerken, K. (Administrative Promotor)
1/01/24 → 31/12/30
Project: Fundamental
-
EUPOM129: Erasmus Standard Budget-based + LS Type II : European Universities Transforming to an Open Inclusive Academy - Making Organisational and Real Evolution (EUTOPIA – MORE)
Vanderkerken, K. (Administrative Promotor), De Potter, L. (CoI (Co-Promotor)) & Bellotti, M. (Administrative Promotor)
1/12/22 → 30/11/26
Project: Applied
-
SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy
Vanderkerken, K. (Administrative Promotor), Breckpot, K. (Co-Promotor) & Menu, E. (Co-Promotor)
1/11/22 → 31/10/27
Project: Fundamental
Research output
-
AXL-Specific Single-Domain Antibodies: A Novel Diagnostic and Therapeutic Strategy in PDAC
Denis, A., Michiels, E., Baldan, J., Satilmis, H., Zhan, D., Vandewalle, N., De Bruyne, E., Menu, E., Vanderkerken, K., Breckpot, K., Devoogdt, N., Rooman, I. & De Veirman, K., 6 Feb 2026. 1 p.Research output: Unpublished contribution to conference › Poster
-
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
Tu, C., Van der Vreken, A., Meeus, F., van den Broecke, L., Brons, J., De Veirman, K., Vanderkerken, K., De Bruyne, E., Breckpot, K. & Menu, E., Dec 2026, In: Experimental Hematology and Oncology. 15, 1, 6 p., 1.Research output: Contribution to journal › Article › peer-review
Open Access -
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
Satilmis, H., Denis, A., Verheye, E., Van der Vreken, A., Zhan, D., Calliauw, E., Törngren, M., Eriksson, H., Faict, S., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 4 May 2026, (E-pub ahead of print) In: Journal of Experimental & Clinical Cancer Research.Research output: Contribution to journal › Article › peer-review
Open Access -
Neural control of Immunotherapy: how Tumor-innervation shapes Anti-Tumor immune responses
Satilmis, H., Denis, A., Vanderkerken, K., Bruyne, E. D., Menu, E., Sloan, E. K. & De Veirman, K., Feb 2026, In: Brain, Behavior, and Immunity. 132, 12 p., 106239.Research output: Contribution to journal › Article › peer-review
-
The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism
Tu, C., Van der Vreken, A., Faict, S., Ates, G., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 1 Mar 2026, In: Cancer Letters. 640, 15 p., 218245.Research output: Contribution to journal › Article › peer-review
Datasets
-
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
Laoui, D. (Creator), Kancheva, D. (Creator), Satilmis, H. (Creator), Vandewalle, N. (Creator), Fan, R. (Creator), Bardet, P. (Creator), Clappaert, E. (Creator), Verstaen, K. (Creator), De Becker, A. (Creator), Vanderkerken, K. (Creator) & De Veirman, K. (Creator), NCBI Gene Expression Omnibus, 14 Nov 2024
Dataset
-
Syntenin inhibition impairs stroma-tumor communication in Multiple Myeloma and improves Bortezomib treatment efficiency
Tu, C. (Creator), Leblanc, R. (Creator), Van der Vreken, A. (Creator), Koops, M. (Creator), Audebert, S. (Creator), Goullieux, L. (Creator), Meeusen, S. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator), Vanderkerken, K. (Creator), David, G. (Creator), Cupedo, T. (Creator), Zimmermann, P. (Creator) & Menu, E. (Creator), Proteomics Identifications Database (PRIDE), 26 Jul 2025
https://www.ebi.ac.uk/pride/archive/projects/PXD064458
Dataset
-
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Menu, E. (Creator), Oudaert, I. (Creator), Vanderkerken, K. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator), Van der Vreken, A. (Creator), Ates, G. (Creator), Massie, A. (Creator) & Maes, K. (Creator), DRYAD, 9 Mar 2026
Dataset
-
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
Menu, E. (Creator), Van der Vreken, A. (Creator), Tu, C. (Creator), De Bruyne, E. (Creator), van den Broecke, L. (Creator), Meeus, F. (Creator), Brons, J. (Creator), De Veirman, K. (Creator), Vanderkerken, K. (Creator) & Breckpot, K. (Creator), Gene Expression Omnibus (GEO), 11 Sept 2025
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307311
Dataset
-
Dataset of AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Creator), Satilmis, H. (Creator), Verheye, E. (Creator), Wang, Y. (Creator), De Groof, T. (Creator), Bridoux, J. (Creator), Kerre, T. (Creator), De Beule, N. (Creator), De Becker, A. (Creator), De Bruyne, E. (Creator), Menu, E. (Creator), Vanderkerken, K. (Creator), Breckpot, K. (Creator), Devoogdt, N. (Creator) & De Veirman, K. (Creator), Theranostics, 15 Apr 2024
DOI: 10.7150/thno.91456, https://zenodo.org/records/15111364
Dataset
Prizes
-
ASH abstract achievement award
Satilmis, H. (Recipient), Denis, A. (Recipient), Verheye, E. (Recipient), De Bruyne, E. (Recipient), Menu, E. (Recipient), Törngren, M. (Recipient), Eriksson, H. (Recipient), Vanderkerken, K. (Recipient) & De Veirman, K. (Recipient), 31 Oct 2025
Prize: Prize (including medals and awards)
-
Award of the Association for International Cancer Research
Vanderkerken, K. (Recipient), 2004
Prize: Prize (including medals and awards)
-
Best Poster Presentation BHS 2025
Van Hemelrijck, L. A. (Recipient), Wang, Y. (Recipient), Muylaert, C. (Recipient), Olsen, C. (Recipient), De Veirman, K. (Recipient), Vanderkerken, K. (Recipient), Menu, E. (Recipient) & De Bruyne, E. (Recipient), 7 Feb 2025
Prize: Prize (including medals and awards)
-
Hilde Bruers Award
Vanderkerken, K. (Recipient), 29 Feb 2008
Prize: Prize (including medals and awards)
-
Junior Award Multiple Myeloma Research Foundation
Vanderkerken, K. (Recipient), 2001
Prize: Prize (including medals and awards)
Activities
-
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of Multiple Myeloma
Satilmis, H. (Speaker), Denis, A. (Contributor), Verheye, E. (Contributor), Van der Vreken, A. (Contributor), Zhan, D. (Contributor), Calliauw, E. (Contributor), Törngren, M. (Contributor), Eriksson, H. (Contributor), Faict, S. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor) & De Veirman, K. (Contributor)
6 Feb 2026Activity: Talk or presentation › Talk or presentation at a conference
-
MAT2A targeting resets the aberrant methylation landscape and DNA damage response in multiple myeloma, uncovering new potential combination strategies.
Van Hemelrijck, L. A. (Speaker), Wang, Y. (Speaker), Muylaert, C. (Speaker), Olsen, C. (Speaker), Vanderkerken, K. (Speaker), De Veirman, K. (Speaker), Menu, E. (Speaker) & De Bruyne, E. (Speaker)
6 Feb 2026Activity: Talk or presentation › Talk or presentation at a conference
-
AXL-specific Single-Domain Antibodies Modulate the Immune Microenvironment and Enhance Checkpoint Blockade in AML
Zhan, D. (Presenter), Vandewalle, N. (Contributor), Satilmis, H. (Contributor), Verheye, E. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor), Breckpot, K. (Contributor), Devoogdt, N. (Contributor) & De Veirman, K. (Contributor)
25 Sept 2025Activity: Talk or presentation › Talk or presentation at a conference
-
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Presenter), Satilmis, H. (Contributor), Verheye, E. (Contributor), Wang, Y. (Contributor), De Groof, T. (Contributor), De Beule, N. (Contributor), kerre, T. (Contributor), De Beule, N. (Contributor), De Becker, A. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor), Breckpot, K. (Contributor), Devoogdt, N. (Contributor) & De Veirman, K. (Contributor)
12 Mar 2024Activity: Talk or presentation › Talk or presentation at a conference
-
AXL targeting using Bemcentinib increases chemosensitivity in Acute Myeloid Leukemia
Vandewalle, N. (Speaker), Meysman, L. (Contributor), De Beule, N. (Contributor), De Becker, A. (Contributor), Satilmis, H. (Contributor), Verheye, E. (Contributor), Fan, R. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor), Breckpot, K. (Contributor), Devoogdt, N. (Contributor) & De Veirman, K. (Contributor)
3 Feb 2023Activity: Talk or presentation › Talk or presentation at a conference